Elanco Animal Health Incorporated
Elanco Animal Health Incorporated is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Indianapolis, IN. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $4.7 billion and a loss of $232 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.0 out of ten, 9 of 9 metrics filed: past 6.7 out of ten, present 6.8 out of ten, future 4.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2018. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 6.5 out of ten. +5.5% a year over 10 filed years; profitable in 3 of 10. 65th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 4.7 out of ten. Share count grew 0.5% a year. 0% of cash flow returned. Insiders: 0 sales, 11 purchases. 47th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 6.1 out of ten. ROE -4%: lost 4¢ per shareholder dollar. Leverage 51%: owes 51¢ per asset dollar. 61st percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 6.9 out of ten. top 31% of 314 in its family; net margin -4.9%. 69th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 7.8 out of ten. top 22% of 315 in its family for leadership; chief executive since 2018. 78th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 3.1 out of ten. bottom 31% of 272 in its family for room to expand. 31st percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.5 out of ten. top 45% of 307 in its family for growth drivers. 55th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 5.3 out of ten. top 47% of 234 in its family for expectations against reality. 53rd percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-24 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-10-06. Filings on record since 2018. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Pet Health 49%, Cattle 24%, Poultry 18%, Swine 8%, Contract Manufacturing 1%. By geography: International 53%, United States 47%. As tagged in its annual report (Form 10-K, filed 2026-02-24).
Who runs it
Simmons, Jeffrey N (PRESIDENT, CEO AND DIRECTOR); Hoover, R David (Chairman of the Elanco Board of Directors); Kinard, David S (Executive Vice President, Human Resources, Corporate Affairs and Administration); De, Brabander Ellen (Executive Vice President, Research, Development and Regulatory Affairs); Correia, De Simas Jose Manuel (Executive Vice President, US Farm Animal Business); Bettington, Timothy J (Executive Vice President, Center of Strategic Growth); Cabral, Ramiro Martin (Executive Vice President - Elanco International); Vanhimbergen, Robert M (EVP and CFO); Meer, James M (CHIEF ACCOUNTING OFFICER); O'Neill, Shiv (GC AND CORP SEC); and 11 more. 21 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-06.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.